Cancer immunotherapy: synthetic and natural peptides in the balance.
Immunol Today
; 20(10): 457-62, 1999 Oct.
Article
en En
| MEDLINE
| ID: mdl-10500293
ABSTRACT
The identification of human tumor-associated antigens has opened new avenues for immune intervention in cancer. Clinical trials using synthetic peptides that match segments of known tumor-associated proteins are ongoing. Alternatively, naturally processed peptides, obtained by acid treatment of tumor cells can be used. Here, Matteo Bellone and colleagues discuss the advantages and disadvantages of synthetic versus natural tumor peptides in cancer immunotherapy.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Inmunoterapia
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Immunol Today
Año:
1999
Tipo del documento:
Article
País de afiliación:
Italia